EFFECTIVENESS OF DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER IN THE FIRST TREATMENT LINE

被引：0
|
作者：
Villa, J. C. [1 ]
Espinosa, J. [1 ]
Gomez, R. [1 ]
Sanchez, V [1 ]
Lopez, R. [1 ]
Galan, R. [1 ]
Pineda, M. D. [1 ]
Perez, M. [1 ]
机构：
[1] Ciudad Real Univ Gen Hosp, Ciudad Real, Spain
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.236
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN8
引用
收藏
页码：A816 / A817
页数：2
相关论文
共 50 条
  • [31] Enzalutamide Treatment in Metastatic Castration-resistant Prostate Cancer: Before and after Docetaxel
    Bilgetekin, Irem
    Basal, Fatma Bugdayci
    Cinkir, Havva Yesil
    Esin, Ece
    Oksuzoglu, Berna
    Demirci, Umut
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2020, 30 (08): : 815 - 821
  • [32] Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer
    E S Antonarakis
    A J Armstrong
    Prostate Cancer and Prostatic Diseases, 2011, 14 : 192 - 205
  • [33] Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
    Schrader, Andres Jan
    Boegemann, Martin
    Ohlmann, Carsten-H.
    Schnoeller, Thomas J.
    Krabbe, Laura-Maria
    Hajili, Turkan
    Jentzmik, Florian
    Stoeckle, Michael
    Schrader, Mark
    Herrmann, Edwin
    Cronauer, Marcus V.
    EUROPEAN UROLOGY, 2014, 65 (01) : 30 - 36
  • [34] A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer
    Courtney, Kevin D.
    Manola, Judith B.
    Elfiky, Aymen A.
    Ross, Robert
    Oh, William K.
    Yap, Jeffrey T.
    Van den Abbeele, Annick D.
    Ryan, Christopher W.
    Beer, Tomasz M.
    Loda, Massimo
    Priolo, Carmen
    Kantoff, Philip
    Taplin, Mary-Ellen
    CLINICAL GENITOURINARY CANCER, 2015, 13 (02) : 113 - 123
  • [35] PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium
    Pei, Xinqi
    Wu, Kaijie
    Sun, Yinghao
    Xu Gao
    Gou, Xin
    Xu, Jun
    Gao, Fan
    He, Dalin
    Li, Lei
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (01) : 2.e11 - 2.e17
  • [36] Docetaxel Still the Optimal First Choice for Symptomatic Metastatic Castration-Resistant Prostate Cancer
    Dreicer, Robert
    Li, Jing
    Armstrong, Andrew J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (05) : 293 - +
  • [37] Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
    K L Mahon
    H-M Lin
    L Castillo
    B Y Lee
    M Lee-Ng
    M D Chatfield
    K Chiam
    S N Breit
    D A Brown
    M P Molloy
    G M Marx
    N Pavlakis
    M J Boyer
    M R Stockler
    R J Daly
    S M Henshall
    L G Horvath
    British Journal of Cancer, 2015, 112 : 1340 - 1348
  • [38] Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
    Marin-Aguilera, Mercedes
    Codony-Servat, Jordi
    Kalko, Susana G.
    Fernandez, Pedro L.
    Bermudo, Raquel
    Buxo, Elvira
    Jose Ribal, Maria
    Gascon, Pedro
    Mellado, Begona
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (02) : 329 - 339
  • [39] Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer
    Kuramoto, Tomomi
    Inagaki, Takeshi
    Fujii, Reona
    Sasaki, Yumiko
    Nishizawa, Satoshi
    Nanpo, Yoshihito
    Matusmura, Nagahide
    Kohjimoto, Yasuo
    Hara, Isao
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (05) : 890 - 897
  • [40] Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC).
    Gernone, A.
    Pagliarulo, A.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345